HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
Japanese regulators approved Alpha DaRT for head and neck cancer, providing HekaBio and Alpha Tau Medical their first market outside Israel.
Why it mattersJapan approval for head and neck cancer Alpha DaRT suggests regulatory path viability for regional market expansion.
Entities Mentioned
HekaBioAlpha Tau Medical